{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:58:58Z","timestamp":1772449138476,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Merck Healthcare GmbH, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15753-5","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:23:38Z","timestamp":1772029418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ERBITAG: Non-interventional study on the efficacy of cetuximab in first-line therapy in patients with RAS wild-type metastatic colorectal cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Stephan W.","family":"Sahm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf Peter","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark-Oliver","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schwittay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Maintz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Goehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Rubanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Hering-Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Overkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"3","key":"15753_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"15753_CR2","doi-asserted-by":"publisher","first-page":"102823","DOI":"10.1016\/j.critrevonc.2019.102823","volume":"145","author":"CC Wu","year":"2020","unstructured":"Wu CC, Wang JH, Lin PC, Liang CA, Huang CY, Lien HC, et al. Tumor sidedness and efficacy of first-line therapy in patients with RAS\/BRAF wild-type metastatic colorectal cancer: A network meta-analysis. Crit Rev Oncol Hematol. 2020;145:102823.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"15753_CR3","first-page":"653","volume":"30","author":"M Zacharakis","year":"2010","unstructured":"Zacharakis M, Xynos ID, Lazaris A, Smaro T, Kosmas C, Dokou A, et al. Predictors of survival in stage IV metastatic colorectal cancer. Anticancer Res. 2010;30(2):653\u201360.","journal-title":"Anticancer Res"},{"issue":"23","key":"15753_CR4","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1002\/cncr.32163","volume":"125","author":"S Piawah","year":"2019","unstructured":"Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139\u201347.","journal-title":"Cancer"},{"key":"15753_CR5","doi-asserted-by":"crossref","unstructured":"Ohishi T, Kaneko MK, Yoshida Y, Takashima A, Kato Y, Kawada M. Current Targeted Therapy for Metastatic Colorectal Cancer. Int J Mol Sci. 2023;24(2).","DOI":"10.3390\/ijms24021702"},{"issue":"8","key":"15753_CR6","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386\u2013422.","journal-title":"Ann Oncol"},{"issue":"3","key":"15753_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329\u201359.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"15753_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023;41(3):678\u2013700.","journal-title":"J Clin Oncol"},{"issue":"5A","key":"15753_CR9","first-page":"3355","volume":"27","author":"D Patel","year":"2007","unstructured":"Patel D, Lahiji A, Patel S, Franklin M, Jimenez X, Hicklin DJ, et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res. 2007;27(5A):3355\u201366.","journal-title":"Anticancer Res"},{"issue":"8","key":"15753_CR10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/14712598.5.8.1085","volume":"5","author":"B Burtness","year":"2005","unstructured":"Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther. 2005;5(8):1085\u201393.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"15753_CR11","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1158\/1535-7163.MCT-18-0694","volume":"17","author":"Y Sunakawa","year":"2018","unstructured":"Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, et al. Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer. Mol Cancer Ther. 2018;17(12):2788\u201395.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"15753_CR12","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ng.115","volume":"40","author":"KM Haigis","year":"2008","unstructured":"Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 2008;40(5):600\u20138.","journal-title":"Nat Genet"},{"key":"15753_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2015.11.025","volume":"55","author":"A Rowland","year":"2016","unstructured":"Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. Eur J Cancer. 2016;55:122\u201330.","journal-title":"Eur J Cancer"},{"issue":"6","key":"15753_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41416-019-0526-2","volume":"121","author":"J Taieb","year":"2019","unstructured":"Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A. Exploring the best treatment options for BRAF-mutant metastatic colon cancer. Br J Cancer. 2019;121(6):434\u201342.","journal-title":"Br J Cancer"},{"issue":"6892","key":"15753_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature"},{"issue":"6","key":"15753_CR16","doi-asserted-by":"publisher","first-page":"100603","DOI":"10.1016\/j.esmoop.2022.100603","volume":"7","author":"E Martinelli","year":"2022","unstructured":"Martinelli E, Cremolini C, Mazard T, Vidal J, Virchow I, Tougeron D, et al. Real-world first-line treatment of patients with BRAF(V600E)-mutant metastatic colorectal cancer: the CAPSTAN CRC study. ESMO Open. 2022;7(6):100603.","journal-title":"ESMO Open"},{"key":"15753_CR17","doi-asserted-by":"crossref","unstructured":"Gutierrez ME, Price KS, Lanman RB, Nagy RJ, Shah I, Mathura S et al. Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. JCO Precis Oncol. 2019;3.","DOI":"10.1200\/PO.19.00274"},{"key":"15753_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87\u201398.","journal-title":"Eur J Cancer"},{"issue":"2","key":"15753_CR19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2017","unstructured":"Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2017;3(2):194\u2013201.","journal-title":"JAMA Oncol"},{"issue":"1","key":"15753_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamasurg.2017.3466","volume":"153","author":"MA Aljehani","year":"2018","unstructured":"Aljehani MA, Morgan JW, Guthrie LA, Jabo B, Ramadan M, Bahjri K, et al. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer. JAMA Surg. 2018;153(1):60\u20137.","journal-title":"JAMA Surg"},{"issue":"3","key":"15753_CR21","first-page":"170","volume":"17","author":"N Boeckx","year":"2018","unstructured":"Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, et al. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. Clin Colorectal Cancer. 2018;17(3):170\u2013e83.","journal-title":"Clin Colorectal Cancer"},{"key":"15753_CR22","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3389\/fonc.2020.00964","volume":"10","author":"A Bahl","year":"2020","unstructured":"Bahl A, Talwar V, Sirohi B, Mehta P, Arya D, Shrivastava G, et al. Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC). Front Oncol. 2020;10:964.","journal-title":"Front Oncol"},{"issue":"8","key":"15753_CR23","first-page":"755","volume":"12","author":"OK Glebov","year":"2003","unstructured":"Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev. 2003;12(8):755\u201362.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"15753_CR24","unstructured":"Dean L, Kane M. Cetuximab Therapy and RAS and BRAF Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries. Bethesda (MD)2012."},{"issue":"1","key":"15753_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10\u201332.","journal-title":"Ann Oncol"},{"issue":"3","key":"15753_CR26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/sj.bjc.6604488","volume":"99","author":"H Brenner","year":"2008","unstructured":"Brenner H, Hoffmeister M, Haug U. Should colorectal cancer screening start at the same age in European countries? Contributions from descriptive epidemiology. Br J Cancer. 2008;99(3):532\u20135.","journal-title":"Br J Cancer"},{"issue":"10","key":"15753_CR27","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","volume":"48","author":"C Bokemeyer","year":"2012","unstructured":"Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012;48(10):1466\u201375.","journal-title":"Eur J Cancer"},{"issue":"3","key":"15753_CR28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41416-020-01140-9","volume":"124","author":"V Heinemann","year":"2021","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, et al. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Br J Cancer. 2021;124(3):587\u201394.","journal-title":"Br J Cancer"},{"issue":"30","key":"15753_CR29","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1200\/JCO.2018.78.3183","volume":"36","author":"S Qin","year":"2018","unstructured":"Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, et al. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. J Clin Oncol. 2018;36(30):3031\u20139.","journal-title":"J Clin Oncol"},{"issue":"14","key":"15753_CR30","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408\u201317.","journal-title":"N Engl J Med"},{"issue":"5","key":"15753_CR31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663\u201371.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15753_CR32","first-page":"129","volume":"17","author":"M Rouyer","year":"2018","unstructured":"Rouyer M, Francois E, Cunha AS, Monnereau A, Noize P, Robinson P, et al. Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort. Clin Colorectal Cancer. 2018;17(2):129\u201339.","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"15753_CR33","first-page":"3674","volume":"16","author":"H Tanioka","year":"2018","unstructured":"Tanioka H, Asano M, Yoshida R, Waki N, Uno F, Ishizaki M, et al. Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study. Oncol Lett. 2018;16(3):3674\u201380.","journal-title":"Oncol Lett"},{"issue":"10","key":"15753_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.5306\/wjco.v11.i10.761","volume":"11","author":"J Martin","year":"2020","unstructured":"Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow HK, et al. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol. 2020;11(10):761\u2013808.","journal-title":"World J Clin Oncol"},{"issue":"15","key":"15753_CR35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, et al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2023;329(15):1271\u201382.","journal-title":"JAMA"},{"issue":"8","key":"15753_CR36","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713\u201329.","journal-title":"Ann Oncol"},{"issue":"1","key":"15753_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41698-025-00892-y","volume":"9","author":"M Abdel Hamid","year":"2025","unstructured":"Abdel Hamid M, Pammer LM, Oberparleiter S, G\u00fcnther M, Amann A, Gruber RA, et al. Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies. NPJ precision Oncol. 2025;9(1):116.","journal-title":"NPJ precision Oncol"},{"issue":"15suppl","key":"15753_CR38","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","volume":"34","author":"AP Venook","year":"2016","unstructured":"Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O\u2019Neil BH, et al. Impact of primary (1\u00ba) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB\/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(15suppl):3504.","journal-title":"J Clin Oncol"},{"issue":"4suppl","key":"15753_CR39","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1200\/JCO.2018.36.4_suppl.830","volume":"36","author":"Z-X Wang","year":"2018","unstructured":"Wang Z-X, He M-m, Wang Y-N, Wang F, Xu R-h. Predictive value of primary tumor location (TL) in patients (pts) with pan-RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving chemotherapy (CTX) \u00b1 cetuximab or panitumumab (C\/P): An updated meta-analysis. J Clin Oncol. 2018;36(4suppl):830.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15753_CR40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Muro K, Watanabe J, Yamazaki K, Ohori H, Shiozawa M, et al. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nat Med. 2024;30(3):730\u20139.","journal-title":"Nat Med"},{"issue":"7","key":"15753_CR41","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/annonc\/mdy140","volume":"29","author":"C Cremolini","year":"2018","unstructured":"Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, et al. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Ann Oncol. 2018;29(7):1528\u201334.","journal-title":"Ann Oncol"},{"issue":"1","key":"15753_CR42","doi-asserted-by":"publisher","first-page":"e15980","DOI":"10.1371\/journal.pone.0015980","volume":"6","author":"Z Saridaki","year":"2011","unstructured":"Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >\/= 2 line cetuximab-based therapy of colorectal cancer patients. PLoS ONE. 2011;6(1):e15980.","journal-title":"PLoS ONE"},{"key":"15753_CR43","doi-asserted-by":"publisher","first-page":"v218","DOI":"10.1093\/annonc\/mdz246.053","volume":"30","author":"SW Sahm","year":"2019","unstructured":"Sahm SW, Zahn MO, Maintz C, Goehler T, Janssen J, Hering-Schubert C, et al. Impact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG. Ann Oncol. 2019;30:v218.","journal-title":"Ann Oncol"},{"issue":"2","key":"15753_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3748\/wjg.v22.i2.501","volume":"22","author":"J Gagniere","year":"2016","unstructured":"Gagniere J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol. 2016;22(2):501\u201318.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"15753_CR45","doi-asserted-by":"publisher","first-page":"e1665973","DOI":"10.1080\/2162402X.2019.1665973","volume":"8","author":"XZ Huang","year":"2019","unstructured":"Huang XZ, Gao P, Song YX, Xu Y, Sun JX, Chen XW, et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients. Oncoimmunology. 2019;8(12):e1665973.","journal-title":"Oncoimmunology"},{"issue":"4","key":"15753_CR46","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00280-019-03927-x","volume":"84","author":"SI Rothschild","year":"2019","unstructured":"Rothschild SI, Betticher D, Zenhausern R, Anchisi S, von Moos R, Pless M, et al. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. Cancer Chemother Pharmacol. 2019;84(4):881\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"34","key":"15753_CR47","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"A Scope","year":"2007","unstructured":"Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25(34):5390\u20136.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15753_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/codi.12826","volume":"17","author":"K Kotake","year":"2015","unstructured":"Kotake K, Asano M, Ozawa H, Kobayashi H, Sugihara K. Tumour characteristics, treatment patterns and survival of patients aged 80 years or older with colorectal cancer. Colorectal Dis. 2015;17(3):205\u201315.","journal-title":"Colorectal Dis"},{"issue":"5","key":"15753_CR49","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41416-022-01854-y","volume":"127","author":"LE Fischer","year":"2022","unstructured":"Fischer LE, Stintzing S, von Weikersthal LF, Modest DP, Decker T, Kiani A, et al. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3. Br J Cancer. 2022;127(5):836\u201343.","journal-title":"Br J Cancer"},{"key":"15753_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2017.10.028","volume":"88","author":"DP Modest","year":"2018","unstructured":"Modest DP, Denecke T, Pratschke J, Ricard I, Lang H, Bemelmans M, et al. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. Eur J Cancer. 2018;88:77\u201386.","journal-title":"Eur J Cancer"},{"issue":"11","key":"15753_CR51","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1002\/cam4.888","volume":"5","author":"C Pinto","year":"2016","unstructured":"Pinto C, Di Fabio F, Rosati G, Lolli IR, Ruggeri EM, Ciuffreda L, et al. Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study. Cancer Med. 2016;5(11):3272\u201381.","journal-title":"Cancer Med"},{"key":"15753_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2021.12.007","volume":"163","author":"D Papamichael","year":"2022","unstructured":"Papamichael D, Lopes GS, Olswold CL, Douillard JY, Adams RA, Maughan TS, et al. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer >\/= 70 years. Eur J Cancer. 2022;163:1\u201315.","journal-title":"Eur J Cancer"},{"issue":"6","key":"15753_CR53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1440-1827.2007.02101.x","volume":"57","author":"T Arai","year":"2007","unstructured":"Arai T, Takubo K. Clinicopathological and molecular characteristics of gastric and colorectal carcinomas in the elderly. Pathol Int. 2007;57(6):303\u201314.","journal-title":"Pathol Int"},{"key":"15753_CR54","doi-asserted-by":"crossref","unstructured":"Bachet JB, Carrasco J, Bolliet M, Le Malicot K, Mineur L, Jourdan SB, et al. 727MO FOLFOX plus PANITUMUMAB (Pmab) according to a stop-and-go strategy in first-line in patients (pts) with non-mutated RAS\/BRAF metastatic colorectal cancer(mCRC): Results of the FFCD 1605 \u2013 OPTIPRIME phase II trial. Annals of Oncology.2025;36:S508.","DOI":"10.1016\/j.annonc.2025.08.1302"},{"key":"15753_CR55","doi-asserted-by":"crossref","unstructured":"Leite LF, Noronha MM, de Menezes JSA, da Concei\u00e7\u00e3o LD, Almeida LFC, Cappellaro AP et al. Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance. Cancers. 2025;17(17).","DOI":"10.3390\/cancers17172804"},{"key":"15753_CR56","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1200\/JCO.2025.43.16_suppl.3513","volume":"43","author":"L Weiss","year":"2025","unstructured":"Weiss L, Heinemann V, Fischer von Weikersthal L, Kaiser F, Fuchs M, Prager GW, et al. FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab. J Clin Oncol. 2025;43:3513\u20133513.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15753-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15753-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15753-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:09:23Z","timestamp":1772446163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15753-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15753"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15753-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The methods were carried out following the relevant guidelines and regulations. The ERBITAG study was conducted in accordance with the Declaration of Helsinki. Approval was granted by the ethics committee of the coordinating investigator (ethics committee of the Medical Association of Westphalia-Lippe and the Medical Faculty of the Westphalia Wilhelms University M\u00fcnster). All study-relevant data were documented in a pseudonymous manner. Patients provided written informed consent prior to inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SWS holds shares and stock options from Merck and received honoraria from MSD and research grant\/funding from Merck. UPN received honoraria from Merck, Astellas, Dr. Falk Pharma international, Astra Zeneca, Roche AG, Amgen, and Bristol Myers Squibb. MOZ holds shares and stock options from Gilead and Bayer and received honoraria from Bristol Myers Squibb, Astra Zeneca, NCO, Novartis, and IOMEDICO. CHS received honoraria from Novartis, and Sanofi and act as a consultant for Amgen, JJ receives sponsorship for advisory boards and study participation from the following companies: BMS, Novartis, Astra Zeneca, Roche, Pfizer, Johnson and Johnson and Ipsen. KS is a fulltime employee at Merck Germany Healthcare GmbH. JR is a fulltime employee at Merck Germany Healthcare GmbH. All other authors have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"311"}}